Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Diabetes Care. 2020 Nov;43(11):2804-2811. doi: 10.2337/dc20-0157. Epub 2020 Sep 1.
Bariatric surgery is associated with diabetes remission and prevention of diabetes-related complications. The ABCD, DiaRem, Ad-DiaRem, DiaBetter, and individualized metabolic surgery scores were developed to predict short- to medium-term diabetes remission after bariatric surgery. However, they have not been tested for predicting durable remission nor the risk of diabetes complications, nor compared with diabetes duration alone.
We identified 363 individuals from the surgically treated group in the prospective Swedish Obese Subjects study with preoperative type 2 diabetes and for whom data (preoperative age, BMI, C-peptide, HbA, oral diabetes medications, insulin use, and diabetes duration) were available for calculation of remission scores. Partial remission (after 2 and 10 years) was defined as blood glucose <6.1 mmol/L or HbA <6.5% (48 mmol/mol) and no diabetes medication. Information on diabetes complications (at baseline and over 15 years of follow-up) was obtained from national health registers. Discrimination was evaluated by area under receiver operating characteristic curves (AUROCs).
For 2-year diabetes remission, AUROCs were between 0.79 and 0.88 for remission scores and 0.84 for diabetes duration alone. After 10 years, the predictive ability of scores decreased markedly (AUROCs between 0.70 and 0.76), and no score had higher predictive capacity than diabetes duration alone (AUROC = 0.73). For development of microvascular and macrovascular diabetes complications over 15 years, AUROCs for remission scores were 0.70-0.80 and 0.62-0.71, respectively, and AUROCs for diabetes duration alone were 0.77 and 0.66, respectively.
Remission scores and diabetes duration are good predictors of short-term diabetes remission. However, for durable remission and risk of complications, remission scores and diabetes duration alone have limited predictive ability.
减重手术可实现糖尿病缓解,并预防糖尿病相关并发症。ABCD、DiaRem、Ad-DiaRem、DiaBetter 和个体化代谢手术评分用于预测减重手术后短期至中期的糖尿病缓解。然而,这些评分尚未经过预测持久缓解和糖尿病并发症风险的检验,也未与糖尿病病程进行比较。
我们从前瞻性瑞典肥胖受试者研究的手术治疗组中确定了 363 名患有 2 型糖尿病的个体,他们具有术前数据(年龄、BMI、C 肽、HbA1c、口服糖尿病药物、胰岛素使用和糖尿病病程),可用于计算缓解评分。部分缓解(术后 2 年和 10 年)定义为血糖<6.1mmol/L 或 HbA1c<6.5%(48mmol/mol)且无需使用糖尿病药物。通过国家健康登记处获得糖尿病并发症(基线和 15 年随访期间)的信息。通过接受者操作特征曲线下面积(AUROC)评估区分度。
对于 2 年的糖尿病缓解,缓解评分的 AUROC 为 0.79-0.88,而糖尿病病程的 AUROC 为 0.84。10 年后,评分的预测能力显著下降(AUROC 为 0.70-0.76),且没有评分比糖尿病病程本身具有更高的预测能力(AUROC=0.73)。对于 15 年期间微血管和大血管糖尿病并发症的发展,缓解评分的 AUROC 分别为 0.70-0.80 和 0.62-0.71,而糖尿病病程的 AUROC 分别为 0.77 和 0.66。
缓解评分和糖尿病病程是短期糖尿病缓解的良好预测指标。然而,对于持久缓解和并发症风险,缓解评分和糖尿病病程本身的预测能力有限。